AirXpanders

AirXpanders, Inc. was a Palo Alto, California-based medical device company founded in 2005 focused on improving breast reconstruction outcomes for women following mastectomy. The company developed and commercialized the AeroForm Tissue Expander System — the world's first needle-free, patient-controlled tissue expansion device using carbon dioxide. Unlike traditional saline expanders that require repeated clinic visits for needle injections, AeroForm allowed patients to control their own expansion via a wireless remote. AirXpanders received regulatory approval in Australia (2013) and the United States (FDA 510(k) clearance) and listed on the Australian Securities Exchange (ASX: AXP) via a A$36.5M IPO in 2015. The company raised additional capital in 2017 via a A$45M private placement. Despite clinical success and commercial launch, AirXpanders filed for Chapter 7 bankruptcy due to commercial challenges.